Delamanid: A new armor in combating drug‑resistant tuberculosis

Xavier, Alphienes Stanley; Lakshmanan, Mageshwaran

doi:10.4103/0976-500X.136121

Molecules of the MillenniumArchivesVol. 5 | Issue 3 | 2014 | pp. 222–224Open Access

Delamanid: A new armor in combating drug‑resistant tuberculosis

¹^*,
¹

¹Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India.

Correspondence: Alphienes Stanley Xavier
Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India.

Published: Jan 1, 2014, Received: Jan 20, 2014, Accepted: Apr 3, 2014

DOI: https://doi.org/10.4103/0976-500X.136121
Article URL: https://www.jpharmacol.com/article/j-pharmacol-pharmacother-5-3-222
PDF URL: https://www.jpharmacol.com/article/j-pharmacol-pharmacother-5-3-222.pdf

Abstract

Intense search has been made in the discovery of newer anti‑TB drugs to tackle the issues such as drug resistance, HIV co‑infection and risk of drug‑drug interactions in the management of TB. Delamanid, a newer mycobacterial cell wall synthesis inhibitor, received a conditional approval from European medicines agency (EMA) for the treatment of MDR‑TB. Preclinical and clinical studies have shown that delamanid has high potency, least risk for drug‑drug interactions and better tolerability.

Keywords

Subject

Readers Also Viewed

Review Article

Clinical Outcomes and Management of Post-varicocelectomy on Male Fertility: A Comprehensive Review

Mohammad Akbar Hossain

Jan 1, 2026

Review Article

Exploring Interleukin-6 Inhibitor Antibodies in Combatting SARS-CoV-2 and its Mutated Variants: Challenges and Future Directions

Mohammed Ali Bakkari, Gassem Ghoal, Fahad Y. Sabei

Jan 1, 2025

Original Research Article

Pharmacogenomics Meets Generative AI: Transforming Clinical Trial Design with Large Language Models

Annisa Fatharani, Ali Alsayegh

Jan 1, 2026